Bacterial vaccines contain mild or killed forms of bacteria that activate the immune system. This is a vital method for preventive medicine to fight infections like tuberculosis, cholera, anthrax, influenza, tetanus, meningitis, and typhoid. Several programs are carried out by governments and non-governmental organizations to spread awareness about the benefits of the preventive medicines including vaccines against infectious diseases.
Market Dynamics:
Global bacterial vaccines market is expected to grow at a substantial rate during the forecast period. This is mainly due to significant initiatives undertaken by governments across the globe to ensure that the preventive medicine for lethal infectious diseases is available for the population across the world. The market is also fueled by the increasing demand for vaccinations during pandemics. Moreover, the market is driven by the launch of new Deoxyribonucleic acid (DNA) vaccines against infectious diseases. The Covid-19 pandemic has influenced the development of a variety of DNA vaccines and hence positively impacted the growth of the bacterial vaccines market. The rising incidence of antibiotic-resistant bacterial diseases is again driving the growth of bacterial vaccines market. This is influencing the key market players to invest in research activities by focusing on developing more effective vaccines against infectious diseases.
However, lack of awareness regarding the bacterial disease is expected to hinder the market growth of the bacterial vaccines
For instance, on September 28, 2023, the U.K. government awarded the University of Birmingham-hosted Bacterial Vaccines Network (BactiVac) US$ 1.4 million in funding to accelerate the development of bacterial vaccines in a bid to prevent infections from occurring as part of the global fight against antimicrobial resistance (AMR). Bacterial vaccines play a critical role in the fight against AMR, both through preventing infections from developing and reducing the need to use antimicrobials.
Key features of the study:
- This report provides in-depth analysis of the global bacterial vaccines market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bacterial vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc., Pfizer Inc., Merck & Co., Inc., Sanofi, Johnson & Johnson Service, Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), AstraZeneca, Novavax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., Valneva SE, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Immunomic Therapeutics, Inc., Moderna, Inc., Clover Biopharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bacterial vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacterial vaccines market
Global Bacterial Vaccines Detailed Segmentation:
- By Vaccine Type
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
- By Patient Age Group
- Pediatric Vaccines (Infants, Children)
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
- By Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
- Others (Oral, Nasal among others)
- By Distribution Channel
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profile
- GSK Plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals